| Drug Name |
Fulvestrant |
| Drug ID |
BADD_D00978 |
| Description |
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer |
| Indications and Usage |
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. |
| Marketing Status |
Prescription |
| ATC Code |
L02BA03 |
| DrugBank ID |
DB00947
|
| KEGG ID |
D01161
|
| MeSH ID |
D000077267
|
| PubChem ID |
104741
|
| TTD Drug ID |
D0JO7Y
|
| NDC Product Code |
64918-1402; 16714-118; 68001-522; 16729-436; 16714-070; 68001-484; 0310-7720; 70860-211; 71731-6121; 70121-1463; 43598-262; 70710-1688; 66529-0014; 68462-317; 70771-1626; 0591-5019; 72603-105; 50923-0416; 0143-9022; 70534-002; 0781-3492; 67457-311; 63323-715; 25021-462; 53183-9305; 68001-424; 65129-2149; 46439-8769; 59057-003; 61662-0011; 0781-3079; 0310-0720; 71288-555; 69910-0001; 68001-510; 70700-284; 58175-0600 |
| Synonyms |
Fulvestrant | 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol | Faslodex | ICI 182780 | ICI 182,780 | ICI-182780 | ICI182780 | ZM 182780 | ZM-182780 | ZM182780 |
